Year: 2011
Type: article
Abstract: Several prior investigations of Alzheimer's disease (AD) patients have indicated naturally occurring autoantibodies against amyloid-β (Aβ) species are produced. Although many studies have focused on the relative concentrations or binding affinities of autoantibodies against Aβ-related proteins in AD and aging, data regarding their functional properties are limited. It is generally believed that these antibodies act to aid in clearance of Aβ. However, as antibodies which bind to Aβ also typically bind to the parent amyloid precursor protein (APP), we reasoned that certain Aβ-targeting autoantibodies may bind to APP thereby altering its conformation and processing. Here we show for the first time, that naturally occurring Aβ-reactive autoantibodies isolated from AD patients, but not from healthy controls, promote β-secretase activity in cultured cells. Furthermore, using monoclonal antibodies to various regions of Aβ, we found that antibodies generated against the N-terminal region, especially Aβ(1-17) , dose dependently promoted amyloidogenic processing of APP viaβ-secretase activation. Thus, this property of certain autoantibodies in driving Aβ generation could be of etiological importance in the development of sporadic forms of AD. Furthermore, future passive or active anti-Aβ immunotherapies must consider potential off-target effects resulting from antibodies targeting the N-terminus of Aβ, as co-binding to the corresponding region of APP may actually enhance Aβ generation.
Source: Journal of Neurochemistry
Institutions: Army Medical University, University of South Florida, Daping Hospital, James A. Haley Veterans' Hospital, Social Insurance Saitama Chuo Hospital, Saitama Medical Center, Saitama Medical University, Saitama Medical University, Heinrich Heine University Düsseldorf, National Center of Neurology and Psychiatry, National Institute of Neuroscience
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: HUCBC modulation of Alzheimer's-like pathology and behavioral changes, Development of a new therapeutic strategy for Alzheimer's disease: Exploration of amyloid-beta inhibitors derived from foods and environment enrichment therapy., Implication of HUCBC: a novel therapeutic strategy for Alzheimer's disease
OpenAlex ID: W1947142382
